BioSpace News Archive

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor conferences:

Immune Regulation, LTD, announced today that the company will give a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:30 a.m. EST.

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21 - Identification of gavo-cel recommended Phase 2 dose and initiation of Phase 2 study expected in 2021 - Initial data from ongoing TC-110 Phase 1/2 trial anticipated in 2021 - IND for third program on track to file in 2021 - Preclinical data from allogeneic TRuC-T cell program targeting mesothelin anticipated in 2021 - Preclinical data presentations from new autologous TRuC-T cell programs anticipated in 2021

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to fight COVID-19, today announced that it will present at the 2021 CTIC 5th Healthcare Investment Summit being held on January 9-10, the H.C. Wainwright BioConnect Conference

Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for projects including the Darwin Tree of Life (DToL; all eukaryotes in Britain and Ireland) and Aquatic Symbiosis G

panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.

Jake Simson, Ph.D., joins Board of Directors Financing proceeds will support the progression of the Company’s first-in-class, oral IL-17 antagonist into clinical trials and advancement of its PPI antagonist pipeline

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference. The fireside chat will be available beginning at 6:00 a.m. ET Monday, January 11, 2021 on the Investors & Media section of the Aldeyra Therapeutics website at https://ir.aldeyra

- Blue Note Therapeutics is developing prescription digital therapeutics specifically designed to treat cancer-related anxiety, depression, and fear of recurrence - Blue Note’s lead product received Breakthrough Device Designation from the FDA in June 2020

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021 at 10:00 a.m. E.T. /7:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:20 a.m. E.T. /7:20 a.m. P.T.